Loteprednol etabonate - Bausch & Lomb

Drug Profile

Loteprednol etabonate - Bausch & Lomb

Alternative Names: Alrex; CDDD-5604; Lotemax; Loteprednol; Loteprednol etabonate; P-5604

Latest Information Update: 10 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmos Corporation
  • Developer Bausch & Lomb; IVAX Corporation; Meda
  • Class Analgesics; Androstadienes; Anti-inflammatories; Antiallergics; Eye disorder therapies; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Ocular inflammation
  • Registered Ocular pain
  • Phase II Keratoconjunctivitis sicca
  • Discontinued Allergic asthma; Allergic rhinitis; Skin disorders

Most Recent Events

  • 05 Sep 2018 Efficacy and adverse events data from a phase III trial in Ocular inflammation and Ocular pain released by Bausch & Lomb
  • 09 Jul 2018 Preregistration for Ocular inflammation (In adults) in USA (Ophthalmic, Gel)
  • 09 Jul 2018 Preregistration for Ocular pain (In adults) in USA (Ophthalmic, Gel)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top